ArisGen SA - Product Pipeline Review - 2015

05:01 EDT 8 Jun 2015 | BioPortfolio Reports

Recently added to the BioPortfolio report store, ArisGen SA - Product Pipeline Review - 2015 is a new report from Global Markets Direct published on 2015-04-28. This 23-page report is available in PDF from $1500.

ArisGen SA - Product Pipeline Review - 2015


Global Markets Direct’s, ‘ArisGen SA - Product Pipeline Review - 2015’, provides an overview of the ArisGen SA’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of ArisGen SA’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


- The report provides brief overview of ArisGen SA including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of ArisGen SA’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the ArisGen SA’s pipeline products

Reasons to buy

- Evaluate ArisGen SA’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of ArisGen SA in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the ArisGen SA’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of ArisGen SA and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to…

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
ArisGen SA Snapshot 4
ArisGen SA Overview 4
Key Information 4
Key Facts 4
ArisGen SA - Research and Development Overview 5
Key Therapeutic Areas 5
ArisGen SA - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
ArisGen SA - Pipeline Products Glance 9
ArisGen SA - Early Stage Pipeline Products 9
Preclinical Products/Combination Treatment Modalities 9
Discovery Products/Combination Treatment Modalities 10
ArisGen SA - Drug Profiles 11
exenatide 11
Product Description 11
Mechanism of Action 11
R&D Progress 11
leuprolide acetate 12
Product Description 12
Mechanism of Action 12
R&D Progress 12
MIF-1 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
octreotide acetate 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
parathyroid hormone 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
insulin human 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
ArisGen SA - Pipeline Analysis 17
ArisGen SA - Pipeline Products by Target 17
ArisGen SA - Pipeline Products by Route of Administration 18
ArisGen SA - Pipeline Products by Molecule Type 19
ArisGen SA - Pipeline Products by Mechanism of Action 20
ArisGen SA - Locations And Subsidiaries 21
Head Office 21
Appendix 22
Methodology 22
Coverage 22
Secondary Research 22
Primary Research 22
Expert Panel Validation 22
Contact Us 22
Disclaimer 23

For more information open ArisGen SA - Product Pipeline Review - 2015.


Original Article: ArisGen SA - Product Pipeline Review - 2015


More From BioPortfolio on "ArisGen SA - Product Pipeline Review - 2015"

Quick Search


Relevant Topics

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...